XOMA Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Financial Statement Detail (Details)

Consolidated Financial Statement Detail (Details)	12 Months Ended			1 Months Ended		12 Months Ended						12 Months Ended		1 Months Ended	12 Months Ended											12 Months Ended
Consolidated Financial Statement Detail (Details)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2012 Five Year Warrants Issued in February 2010 [Member]	Feb. 28, 2010 Five Year Warrants Issued in February 2010 [Member] USD ($)	Dec. 31, 2014 Five Year Warrants Issued in February 2010 [Member] USD ($)	Dec. 31, 2013 Five Year Warrants Issued in February 2010 [Member] USD ($)	Feb. 28, 2010 Five Year Warrants Issued in February 2010 [Member]	Dec. 31, 2014 Five Year Warrants Issued in March 2012 [Member] USD ($)	Dec. 31, 2013 Five Year Warrants Issued in March 2012 [Member] USD ($)	Mar. 31, 2012 Five Year Warrants Issued in March 2012 [Member] USD ($)	Dec. 31, 2014 Two Year Warrants Issued in December 2014 [Member] USD ($)	Dec. 08, 2014 Two Year Warrants Issued in December 2014 [Member] USD ($)	Jun. 30, 2009 Warrants Issued to Private Investors [Member] USD ($)	Dec. 31, 2014 Warrants Issued to Private Investors [Member] USD ($)	Dec. 31, 2013 Warrants Issued to Private Investors [Member] USD ($)	Jun. 30, 2009 Warrants Issued to Private Investors [Member]	Dec. 31, 2014 Equipment and Furniture [Member] USD ($)	Dec. 31, 2013 Equipment and Furniture [Member] USD ($)	Dec. 31, 2014 Buildings, Leasehold and Building Improvements [Member] USD ($)	Dec. 31, 2013 Buildings, Leasehold and Building Improvements [Member] USD ($)	Dec. 31, 2014 Construction-in-Progress [Member] USD ($)	Dec. 31, 2013 Construction-in-Progress [Member] USD ($)	Dec. 31, 2014 Land [Member] USD ($)	Dec. 31, 2013 Land [Member] USD ($)	Dec. 31, 2014 Options Contract [Member] USD ($) Contract	Dec. 31, 2013 Options Contract [Member] USD ($)	Dec. 31, 2012 Options Contract [Member] USD ($)	Dec. 31, 2014 Options Contract [Member] EUR (€)	Dec. 31, 2014 Option Contract 1 [Member] EUR (€)	Dec. 31, 2014 Option Contract 2 [Member] EUR (€)	Dec. 31, 2014 Demand Deposits [Member] USD ($)	Dec. 31, 2013 Demand Deposits [Member] USD ($)	Dec. 31, 2014 Money Market Funds [Member] USD ($)	Dec. 31, 2013 Money Market Funds [Member] USD ($)
Cash and Cash Equivalents [Line Items]
Cash equivalents																																$ 10,800,000	$ 18,900,000	$ 67,600,000	$ 82,800,000
Short-term Investments [Abstract]
Short-term investments	0us-gaap_ShortTermInvestments	19,990,000us-gaap_ShortTermInvestments
Derivative [Line Items]
Notional amount of derivative liability																													15,000,000
Number of foreign exchange option contracts																										2
Derivative, amount of hedged item																														1,500,000	15,000,000
Derivative, premiums																										1,500,000
Derivative fair value																										0	400,000
Derivative, loss																										400,000	100,000	700,000
Receivables [Abstract]
Trade receivables, net	2,993,000us-gaap_AccountsReceivableNetCurrent	3,731,000us-gaap_AccountsReceivableNetCurrent
Other receivables	316,000us-gaap_OtherReceivablesNetCurrent	50,000us-gaap_OtherReceivablesNetCurrent
Total	3,309,000us-gaap_ReceivablesNetCurrent	3,781,000us-gaap_ReceivablesNetCurrent
Property, Plant and Equipment [Line Items]
Property and equipment, gross	38,628,000us-gaap_PropertyPlantAndEquipmentGross	38,216,000us-gaap_PropertyPlantAndEquipmentGross																28,638,000	28,365,000	9,343,000	9,316,000	337,000	225,000	310,000	310,000
Less: Accumulated depreciation and amortization	(33,508,000)	(31,760,000)
Property and equipment, net	5,120,000us-gaap_PropertyPlantAndEquipmentNet	6,456,000us-gaap_PropertyPlantAndEquipmentNet
Depreciation and amortization expense	1,900,000	2,900,000	4,100,000
Accrued Liabilities [Abstract]
Incentive compensation	4,295,000us-gaap_AccruedBonusesCurrent	4,386,000us-gaap_AccruedBonusesCurrent
Accrued payroll and other benefits	3,061,000us-gaap_AccruedSalariesCurrent	3,009,000us-gaap_AccruedSalariesCurrent
Accrued clinical trial costs	1,424,000xoma_AccruedClinicalTrialCosts	878,000xoma_AccruedClinicalTrialCosts
Other	1,112,000us-gaap_OtherAccruedLiabilitiesCurrent	1,661,000us-gaap_OtherAccruedLiabilitiesCurrent
Total	9,892,000us-gaap_AccruedLiabilitiesCurrent	9,934,000us-gaap_AccruedLiabilitiesCurrent
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)								1,260,000	12,109,418	12,562,682	14,834,577		8,097,165				347,826
Exercise price of warrants (in dollars per share)					$ 10.50						$ 1.76		$ 7.90	$ 19.50
Fair value of warrant liability							1,100,000		26,700,000	68,700,000		5,200,000	10,300,000		39,500,000	100,000
Gain (loss) on revaluation of warrant liability						$ 1,100,000						$ 5,100,000			$ 2,500,000
Warrant term				5 years	5 years							2 years		5 years